胶滴肿瘤药敏检测技术与结直肠癌预后之间的关系  

Correlation between the Drug Sensitive Test Technology of Gelatinous Tumor and Prognosis of Colorectal Cancer

作　　者：路万林 张宏[1] LU Wan-lin;ZHANG Hong(Colorectal Cancer Tumor Ward,Fourth Department of General Surgery,Shengjing Hospital Affiliated to China Medical University,Shenyang,Liaoning Province,110004 China)

机构地区：[1]中国医科大学附属盛京医院第四普通外科结直肠肿瘤病房,辽宁沈阳110004

出　　处：《系统医学》2018年第14期129-132,共4页Systems Medicine

摘　　要：目的探讨胶原凝胶滴包埋肿瘤细胞培养法药敏检测技术(CD-DST)与结直肠癌患者预后之间的关系。方法统计2012年6月—2017年6月就诊于中国医科大学附属盛京医院的311例结直肠癌患者,根据术后是否采用CD-DST推荐的化疗方案分为实验组与对照组。其中实验组为进行药敏试验并根据结果指导完成化疗患者132例(其中高敏感89例,低敏感43例),对照组为未进行药敏试验并根据NCCN指南完成化疗患者179例。统计患者年龄,性别,临床分期等基线资料,随访患者生存状态,统计各组患者总生存期。结果两组患者年龄(χ~2=0.651,P=0.42),性别(χ~2=1.225,P=0.268),T分期(χ~2=2.684,P=0.261)等基线资料均差异无统计学意义(P>0.05)。临床Ⅲ期患者中,实验组相对于对照组生存期更长,差异有统计学意义(P=0.029),实验组患者3年生存率88.4%,对照组患者3年生存率60.2%。整体实验组中,高敏感组相对于低敏感组拥有更长生存期,差异有统计学意义(P=0.035),其中,高敏感组患者3年生存率94.2%,低敏感组患者3年生存率81.2%。结论针对Ⅲ期结直肠癌患者使用药敏实验技术指导患者结直肠癌术后化学治疗,可有效延长患者生存期,对结直肠癌个体化治疗具有一定的指导意义。Objective To study the correlation between the drug sensitive test technology of gelatinous tumor and prognosis of colorectal cancer.Methods 311 cases of patients with colorectal cancer in our hospital from June 2012 to June2017 were selected and divided into two groups according to the chemotherapy plan recommended by the CD-DST,including 132 cases undergoing the drug sensitivity test and finishing the chemotherapy according to the results（89 highsensitive cases and 43 low-sensitive cases）,the control group with 179 cases without drug sensitive test and finishing the chemotherapy according to the NCCN guidance,and the age,gender,and clinical staging of patients were counted,and the survival state of patients was followed up,and the total survival period of each group was counted.Results The differences in the age（χ2=0.651,P=0.42）,gender（χ2=1.225,P=0.268） and T staging（χ2=2.684,P=0.261） were not Statistically Significant（P〉0.05）,and in the patients in clinical III,the survival period in the experimental group was longer than that in the control group,the differenct was stistically signifcant（P=0.029）,and the 3-year survival rate in the experimental group and in the control group was respectively 88.4% and 60.2%,and the survival period in the high-sensitive group was longer than that in the low-sensitive group,the differenct was stistically signifcant（P=0.035）,and the 3-year survival rate in the high-sensitive group and the low-sensitive group was respectively 94.2% and81.2%.Conclusion The drug sensitive experimental technology in guiding the chemistry treatment of patients after the stage III colorectal cancer can prolong the survival period of patients,which is of a certain guidance significance to the individualized treatment of rectal cancer.

关 键 词：CD-DST 结直肠癌 化疗 个体化治疗 

分 类 号：R735[医药卫生—肿瘤]